Defective interactions of protein partner with ion channels and transporters as alternative mechanisms of membrane channelopathies  by Kline, Crystal F. & Mohler, Peter J.
Biochimica et Biophysica Acta 1838 (2014) 723–730
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemReview
Defective interactions of protein partner with ion channels and
transporters as alternative mechanisms of
membrane channelopathies☆
Crystal F. Kline, Peter J. Mohler ⁎
The Dorothy M. Davis Heart and Lung Research Institute, Department of Internal Medicine, Division of Cardiovascular Medicine, Department of Physiology & Cell Biology,
The Ohio State University Wexner Medical Center, USA☆ This article is part of a Special Issue entitled: Reciprocal
eton and membrane channels, receptors and transporters. G
⁎ Corresponding author at: Dorothy M. Davis Heart an
Ohio State University Wexner Medical Center, 473 W. 1
USA. Tel.: +1 614 292 7766; fax: + 1614 247 7799.
E-mail address: peter.mohler@osumc.edu (P.J. Mohl
0005-2736/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbamem.2013.05.024a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 February 2013
Received in revised form 15 May 2013
Accepted 21 May 2013
Available online 31 May 2013
Keywords:
Ion channel
Auxiliary subunit
Cardiac arrhythmia
Catecholaminergic polymorphic ventricular
tachycardia
Ankyrin-B syndromeThe past twenty years have revealed the existence of numerous ion channel mutations resulting in human pathol-
ogy. Ion channels provide the basis of diverse cellular functions, ranging from hormone secretion, excitation–
contraction coupling, cell signaling, immune response, and trans-epithelial transport. Therefore, the regulation of
biophysical properties of channels is vital in human physiology. Only within the last decade has the role of
non-ion channel components come to light in regard to ion channel spatial, temporal, and biophysical regulation
inphysiology. A growingnumber of auxiliary components have beendetermined toplay elemental roles in excitable
cell physiology, with dysfunction resulting in disorders and relatedmanifestations. This review focuses on the broad
implications of such dysfunction, focusing on disease-causing mutations that alter interactions between ion chan-
nels and auxiliary ion channel components in a diverse set of human excitable cell disease. This article is part of a
Special Issue entitled: Reciprocal inﬂuences between cell cytoskeleton andmembrane channels, receptors and trans-
porters. Guest Editor: Jean Claude Hervé
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rights reserved.1. Introduction
Most ion channels are recognized as central players of larger
multi-subunit complexes. Ion channels associate with a number of scaf-
folding, anchoring, regulatory, and signaling proteins. Co-targeting of
these auxiliary subunits to the channel complex has evolved to allow
for rapid and localized regulation of ion channels in response to speciﬁc
stimuli. Electrophysiological properties of cells, once thought to be
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auxiliary subunits. While mutations in ion channel genes can cause dys-
function, a growing number of ion channel-associated proteins have
come to the forefront in the study of human excitable cell pathology.
This newparadigmhas emergedbased ongrowing evidence demonstrat-
ing variants in genes involved in the expression, localization, and regula-
tion of ion channels also result in excitable cell disease. These ﬁndings
have expanded the view of excitable cell disease, uncovered new
mechanisms for ion channel regulation, and provided novel targets
for pharmacological treatment of aberrant ion channel activity in
excitable cells.
2. Liddle syndrome: dysregulation of Nedd4-2-mediated regulation
of ENaC and hypertension
The last, and rate-limiting, step in Na+ reabsorption by the kidney
occurs in the distal convoluted tubules, connecting tubules, and
collecting ducts where the epithelial sodium channel (ENaC) regu-
lates Na+ absorption [1,2]. ENaC selectively transports Na+ down an
electrochemical gradient established by the Na+/K+ ATPase at the
basolateral membrane of polarized epithelial cells [3]. Consequently,
the directional movement of Na+ produces an osmotic gradient that
drives the movement of water in the same direction [4–6].
ENaC is selectively expressed at the apical membrane in a variety
of epithelia, such as the kidney, lung, and colon [7]. Since entry of
Na+ through ENaC is the last and rate-limiting step for Na+ absorp-
tion, [3,7,8] regulation of this channel is vital to the regulation of
extracellular ﬂuid volume, blood volume, and blood pressure. The
activity of ENaC is tightly controlled by a number of hormones (al-
dosterone, vasopressin, and insulin) and intracellular mediators
(Na+, Ca2+, pH, cAMP, protein kinases A and C, and extracellular
proteases) [3,9]. The necessity of this tight regulation is illustrated
by the number of human diseases that have been linked to dysfunc-
tion in ENaC, including Liddle syndrome, [10,11] cystic ﬁbrosis, [12]
pseudohypoaldosteronism type I (PHA-I), [13,14] and pulmonary
edema [15,16].
Liddle syndrome, ﬁrst described in 1963, was originally determined
to be an autosomal dominant form of endocrine hypertension [17].
Activating mutations of the epithelial sodium channel (ENaC) were ini-
tially described, resulting in increased sodium reabsorption/potassium
wasting in the distal nephron. As a result, affected patients experience
hypertension, hypokalemia, low aldosterone and renin levels, saltFig. 1. Regulation of ENaC by Nedd4-2. A–B. The ubiquitin ligase Nedd4-2 recognizes PY mo
motif. C. Ubiquitinated ENaC is endocytosed, leading to a reduction in ENaC at the plasma me
to ubiquitination, remain at the plasma membrane, and increase channel activity.sensitivity volume expansion, andmetabolic alkalosis [17]. ENaC is com-
posed of three similar subunits, α, β, and γ. While the stoichiometric
ratio of these subunits in a channel complex is debated, the current
view is a ratio of 1:1:1 [18]. Each subunit consists of intracellular N-
and C-termini, two transmembrane domains, and an extracellular
loop [19]. The C-terminal region of each subunit contains a conserved
proline-rich sequence, called the PY motif [19]. The original gene vari-
ants (frameshifts and premature stop codons) identiﬁed in the etiology
of Liddle syndrome were found to result in the truncation of the
C-terminus, with speciﬁc deletions of the PY motifs (PPxY) of the β
(SCNN1B) and γ (SCNN1G) subunits [10,11].
Sodium absorption through ENaC is altered in two non-mutually
exclusive ways: altering the open probability (Po) of the channel [20]
or varying themembrane density of the channel [21–24]. There is over-
whelming evidence to demonstrate that the most potent down-
regulation of ENaC is via ubiquitination of the membrane channel and
subsequent endocytosis. Liddle syndrome is linked to a defect in the
ubiquitin-mediated down-regulation of β and γ ENaC. Speciﬁcally, it
has been demonstrated that it is the Nedd4-2-mediated ubiquitination
of ENaC that leads to endocytosis of the channel [25] and that dysfunc-
tion in the ability of Nedd4-2 to ubiquitinate ENaC results in enhanced
Na+ absorption and hypertension in Liddle syndrome (Fig. 1) [26].
Speciﬁcally, the E3 ubiquitin ligase Nedd4-2 binds to the PY motif in
the C-terminal regions of ENaC subunits and facilitates ubiquitination
of lysine residues located in the N-terminal domains of the β and γ
ENaC subunits. Nedd4-2 has been shown to effectively suppress ENaC
activity by enhancing the endocytosis of the channel from the apical
membrane [27–30]. Liddle syndrome mutations effectively remove
the PY motifs, resulting in an inability of Nedd4-2 to mediate the
ubiquitination and endocytosis of ENaC. The result is an accumulation
of active channels at the cell surface, sustained Na+ (and ﬂuid) absorp-
tion in the distal nephron, and hypertension. In summary, the dynamic
relationship between ENaC and Nedd4-2 illustrates the complexmech-
anisms underlying human disease as well as potential new molecular
targets to tune membrane excitability.
3. Yotiao and LQT1: PKA-mediated phosphorylation of KCNQ1 and
the development of long QT syndrome
Late phase repolarization of the cardiac action potential is largely
determined by the slow delayed rectiﬁer current, IKs [31]. This cardiac
membrane current is controlled by potassium channel comprised oftifs in wild type ENaC but not mutated forms of the β or γ subunits, which lack the PY
mbrane, reducing activity. On the other hand, mutated forms of ENaC, that are resistant
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[32,33]. Individuals with variants in KCNQ1 or KCNE1 may develop
type 1 or type 5 long QT syndromes, respectively. Speciﬁcally, these pa-
tients demonstrate arrhythmias and sudden cardiac death in response
to stimulation of the sympathetic nervous system [34].
IKs is regulated by stimulation of the sympathetic nervous system,
contributing to shortening of the cardiac action potential despite
concurrent increases in heart rate. β-adrenergic receptors (β-ARs)
modulate excitation–contraction coupling through signaling cascades
that lead to PKA-dependent phosphorylation of several proteins. β-AR
agonists, such as norepinephrine, activate stimulatory G-proteins,
resulting in the activation of adenylate cyclase and an increase in
cAMPproduction. The increase in cAMP activates PKA [35]. Sympathetic
regulation of the cardiac action potential is mediated via PKA-mediated
phosphorylation of KCNQ1 [36,37]. Facilitation of PKA-mediated phos-
phorylation of KCNQ1 requires assembly with the A-kinase anchoring
protein (AKAP) Yotiao (Fig. 2) [38]. A decade ago, Marx and colleagues
identiﬁed Yotiao as a necessary targeting protein for the KCNQ1 channel
complex in the cardiomyocyte [38]. Studies in brain had previously
identiﬁed Yotiao as an AKAP [39,40].
Mutations in KCNQ1 and Yotiaowhich disrupt the complex result in
type 1 and type 11 long QT syndromes, respectively [41]. For example, a
mutation in KCNQ1 (G589D), originally identiﬁed by Piippo and col-
leagues [42], was determined to disrupt the interaction between Yotiao
and IKS complex, rendering the IKS complex insensitive to β-adrenergic
stimulation [38]. As a result, the channel had a signiﬁcantly increased
threshold of activation [38]. Modeling studies suggested that this
mutation was likely to produce QTc prolongation and extrasystoles in
conjunction with sympathetic stimulation [43]. Counterpoint to muta-
tions in KCNQ1, the inherited S1570L mutation in Yotiao also results
in a reduced interaction between Yotiao and the IKS complex [44].
Speciﬁcally, this mutation resides in a region of Yotiao which coordi-
nates its interaction with KCNQ1 [44]. While S1570L does not elim-
inate the interaction with the IKS complex, it produces a signiﬁcant
reduction in its association with KCNQ1, reduces cAMP-induced
KCNQ1 phosphorylation, and eliminates the functional response of
the IKS complex to cAMP [44]. Overall, this results in delayed repolar-
ization of the action potential [44]. Together, these data demonstrate
the necessity of macromolecular complexes for normal cardiac
physiology.Fig. 2. Regulation of IKs by the AKAP Yotiao. A. The IKs channel consists of KCNQ1 α-subunits
phosphatase 1 (PP1) to the IKs channel. Stimulation of the β-adrenergic receptor (β-AR) lea
kinase A. PKA and PP1 regulate IKs via phosphorylation/dephosphorylation activities. B. Mu
come insensitive to β-adrenergic stimulation.4. The ryanodine receptor and CPVT: defects in a macromolecular
regulatory complex
Ryanodine receptors are critical players in cardiac excitation–
contraction coupling, where opening of the plasma membrane L-type
Ca2+ channel triggers an intensiﬁed release of Ca2+ from the sarcoplas-
mic reticulum, i.e. Ca2+-induced Ca2+ release. Cardiac RyRs are primarily
tetramers of RyR2 monomers with large regulatory domains located in
the cytosol [45]. RyR2 channels exist as extensivemacromolecular com-
plexes, comprised of over a dozen regulatory subunits, including cal-
modulin (CaM), protein kinase A (PKA), Ca2+/calmodulin-dependent
kinase II (CaMKII), protein phosphatases I and 2A (PP1, PP2A),
calstabin2 (also known as FK506-binding protein FKBP12.6), phospho-
diesterase 4D3 (PDE4D3), triadin, and calsequestrin [45,46].
Human variants in the RyR2 gene have been linked to human cat-
echolaminergic polymorphic ventricular tachycardia (CPVT), [42,47]
a disease directly linked with sympathetic-dependent polymorphic
arrhythmia with risk of sudden cardiac death. Speciﬁcally, CPVT-
associated gain-of-function variants sensitize RyR2 to activation
by cytosolic Ca2+ [48,49] or delay Ca2+-dependent inactivation [50].
Multiple studies have supported this, demonstrating that cardio-
myocytes isolated from transgenic knock-in mice (heterozygous for
CPVT-associated mutations) show gain-of-function activity, where
catecholamine-induced spontaneous Ca2+ release eventswere observed
[46,51].
In 2003, Marks and colleagues proposed a model to explain the
decreased stability of the closed conformation state of mutant RyR2
channels. While another hypothesis suggested that dysfunctional regu-
lation of RyR2 was due to abnormal intramolecular associations within
the RyR2 molecule [52], the Marks' model suggested a role for the
channel-stabilizing subunit FKBP12.6 [49]. Speciﬁcally, their work pro-
posed that binding to FKBP12.6was decreased in CPVT-linkedmutations
in RyR2. Furtherwork from the group supported thismodel, demonstrat-
ing that the binding afﬁnity of FKBP12.6 is reduced for CPVT-associated
RyR2 mutants [49]. Moreover, several studies have demonstrated that
the dissociation of FKBP12.6 destabilizes the closed state of the channel,
leading to a gain-of-function phenotype [53]. Studies using FKBP12.6
knockoutmice further strengthened the link betweenRyR2-FKBP12.6 in-
teractions and ventricular arrhythmias [49,54]. Following β-adrenergic
stimulation, FKBP12.6−/− mice experience ventricular tachycardia,and KCNE1 β-subunits. The AKAP Yotiao complexes protein kinase A (PKA) and protein
ds to activation of adenylate cyclase, the production of cAMP, and activation of protein
tations which disrupt the association between Yotiao and the IKs channel complex be-
Fig. 3. Regulation of the pancreatic KATP channel by ankyrin-B. Ankyrin-B associates
with the α-subunit of the KATP channel, Kir6.2, via a C-terminal motif in Kir6.2. Associ-
ation with ankyrin-B regulates Kir6.2 plasma membrane expression and KATP channel
ATP sensitivity.
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CPVT-associated mutations in RyR2 [46,51]. Moreover, an experimental
drug used to enhance FKBP12.6 binding to RyR2 (JTV519) inhibits ar-
rhythmias in FKBP12.6+/− mice [55]. Despite these ﬁndings, there is
still controversy involving the role of FKBP12.6 in the pathogenesis of
CPVT [56]. Future studies are needed to fully elucidate the molecular
mechanisms associated with RyR2-associated CPVT in humans.
5. Ankyrins: critical components of the excitable cell membrane
Ankyrins have been established as integral components in the
targeting, retention, and regulation of a number of ion channels, trans-
porters, pumps, and cytosolic proteins in excitable cells. Three ankyrin
gene products, ankyrin-R (ANK1), ankyrin-B (ANK2), and ankyrin-G
(ANK3) are expressed in vertebrates, each with unique expression
proﬁles and disease associations. In the past decade, studies in humans
and mice have illustrated a critical role for ankyrin function in the
heart and pancreatic beta cell. Dysfunction in ankyrin-B has been asso-
ciated with defective intracellular Ca2+ handling (LQT4 or Ankyrin-B
syndrome), aswell as permanent neonatal diabetes mellitus, while dys-
function in ankyrin-G bindingwithNav1.5 has been linkedwith Brugada
syndrome.
5.1. Ankyrin-B syndrome: lost anchors lead to excitable cell disease
Nearly 20 years ago, Schott and colleagues described a French co-
hort displaying an atypical form of long QT syndrome [57]. Affected
family members displayed abnormal T-wave morphology, sinus node
bradycardia, and atrial ﬁbrillation [57]. Notably, certain individuals
displayed stress- and exercise-induced sudden cardiac death [57].
Using linkage analysis, Schott identiﬁed that this fourth locus for con-
genital LQT was associated with an 18 cm region corresponding to the
ANK2 locus (ankyrin-B) [57]. Further analysis revealed a single ANK2
missense variant, A4274G, resulting in E1425G [58].
Since this initial discovery, a number of additional ankyrin-B human
gene variants have been identiﬁed [59–63]. Patients with ANK2 loss-of-
function variants may display sinus node dysfunction, atrial ﬁbrillation,
polymorphic ventricular arrhythmias, and/or conduction defects
[58,60,61]. Studies in mice that are haploinsufﬁcient in ankyrin-B
(ankyrin-B+/−) have been invaluable in the evaluation of molecular
mechanismsunderlying the role of ankyrin-B in excitable cell physiology.
Ankyrin-B+/−mice demonstrate common phenotypes with the original
French LQT4 kindred, including sinus bradycardia, conduction defects,
and catecholamine-induced polymorphic ventricular arrhythmia with
associated syncope/death [58]. Isolated primary cardiac myocytes from
ankyrin-B+/−mice were used to conclude that the E1425G variant was
a loss-of-function variant of ankyrin-B. Ankyrin-B+/− cardiomyocytes
displayed reduced spontaneous contraction rates, aberrant localization
of the Na+/Ca2+ exchanger (NCX), and abnormal calcium transients
[58,64,65]. Rescue experiments using exogenous ankyrin-B successfully
restored wild type myocyte phenotypes [58,64,65]. Conversely,
overexpression of exogenous ankyrin-B E1425G in ankyrin-B+/−
myocytes was unable to restore abnormal phenotypes [58].
Further evaluation revealed that ankyrin-B+/−myocytes expressed
signiﬁcantly less Na+/Ca2+ exchanger (NCX), Na+/K+ ATPase (NKA),
and inositol 1,4,5 trisphosphate receptor (InsP3R) [58]. Additionally, it
was determined that the NCX and NKA were reduced preferentially at
the transverse tubule [58]. Biochemical analyses demonstrated at
ankyrin-B directly associates with the NCX, NKA, and InsP3R [66].
Furthermore, it was established that exogenous expression of ankyrin-B
cDNA in ankyrin-B+/− cardiomyocytes restored proper expression and
localization of the NCX, NKA, and InsP3R [58,60,61,64,66,67]. Eventually
it was determined that loss of ankyrin-B-dependent localization of NCX
and NKA resulted in increased SR Ca2+ load and elevated SR Ca2+ tran-
sients, essentially mimicking the effects of cardiac glycosides [68,69].
These studies have demonstrated that reduced expression/dysfunctionof ankyrin-B can be an underlying cause for human arrhythmia suscepti-
bility by altering myocyte electrical activity.
5.2. Ankyrin-B and the KATP channel: a new component in glucose
homeostasis
The KATP channel is a hetero-octameric structure of four Kir6x pore-
forming subunits and four SUR regulatory subunits [70]. Although KATP
channels were originally identiﬁed in heart, it is the pancreatic KATP
channels that have beenmost thoroughly investigated. In the pancreatic
beta cell, the KATP channel functions as a metabolic sensor, closing the
KATP channel in response to increased blood glucose. Closure of the
KATP channel results in beta cell depolarization, activation of L-type
Ca2+ channels, and stimulation of insulin granule release [71]. Not
surprisingly, mutations in KATP channel genes (KCNJ11 and ABCC8) are
associated with both diabetes mellitus and hyper-insulinemia syn-
dromes (reviewed in [72]). In 2004, a mutation in the Kir6.2 subunit,
E322K, was identiﬁed in a case of permanent neonatal diabetesmellitus
[73]. Several years later, it was determined that thismutation resided in
the region of Kir6.2 that associated with ankyrin-B (Fig. 3) [74]. Specif-
ically, it was determined that the E322K variant disrupts the association
of Kir6.2 with ankyrin-B in vivo and in vitro and also decreases the
sensitivity of the channel to ATP [74]. Based on modeling studies, the
disruption of the Kir6.2/ankyrin-B interaction was proposed to result
in two seemingly opposing phenotypes: a loss-of-function due to loss
of KATP channel density at the membrane and a gain-of-function due
to decreased ATP sensitivity [74]. It is suggested that the combination
of the two phenotypes actually results in a diabetic phenotype less
severe than either a gain-of-function mutation or loss-of-function mu-
tation alone. These data suggest that the disruption of the ankyrin-B/
Kir6.2 complex via the Kir6.2 E322K mutation results in aberrant local-
ization and regulation of the KATP channel. Further, these data illustrate
the complexity of pathways underlying ion channel regulation in health
and disease.
5.3. Ankyrin-G and Nav1.5: Brugada syndrome
Voltage-gated Na+ (Nav) channels are required for normal electrical
activity in a number of cell types, including neurons, skeletal muscle,
and cardiomyocytes [75–81]. Ankyrin-G has been ﬁrmly established as
a critical player in the trafﬁcking of Nav channels in the central nervous
system [82]. In neuronal cells, ankyrin-G is co-expressed with Nav1.2
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neuromuscular junction [83–86]. More speciﬁcally, it has been demon-
strated that ankyrin-G directly associates with Nav channels at these
specialized neuronal membrane domains [85,87]. In 2003, two studies
published independently identiﬁed aunique ankyrin-Gbinding sequence
(ABS) in the cytoplasmic DII/DII loop of Nav1.2 [88,89]. The ABS is a highly
conserved nine amino acid motif [(V/A)P(I/L)AXXE(S/D)] and found in
most Nav channel gene products, including Nav1.1, Nav1.2, Nav1.4,
Nav1.5, and Nav1.6. Based on the presence of both ankyrin-G and Nav1.5
at the cardiac intercalated disc, it was proposed that perhaps ankyrin-G
ﬁlled a similar role in cardiac physiology [61]. Indeed, Bennett and
colleagues demonstrated that an ankyrin-G-dependent pathway was
necessary for proper targeting of Nav1.5 to the intercalated disc [61].
Speciﬁcally, their study demonstrated co-localization of ankyrin-G and
Nav1.5 to the cardiac intercalated disc, that Nav1.5 and ankyrin-G
co-immunoprecipitated from detergent-soluble cardiac lysates, and
that deletion of the ABS rendered Nav1.5 incapable of binding
ankyrin-G [61]. Using primary cardiomyocytes deﬁcient in ankyrin-G
expression, a follow-up study by Lowe and colleagues demonstrated
that loss of ankyrin-G resulted in decreased Nav1.5 protein expression,
decreased Nav1.5 membrane targeting, and reduced cardiomyocyte INa
[79].
Brugada syndrome, a cardiac syndrome characterized by ST segment
elevation, right bundle branch block, and fatal cardiac arrhythmias [90],
had long been attributed to loss of function mutations in SCN5A
(encoding the Nav1.5 channel) [91]. Speciﬁcally, it was believed that
thesemutations altered Nav1.5 channel biophysics or drastically altered
protein structure [92]. However, in 2004, Priori and colleagues screened
a large number of Brugada patients for mutations in the ABS region of
SCN5A [61]. One SCN5A missense mutation was identiﬁed, E1053K
[61]. Work by Bennett et al. determined that E1053K prevented associ-
ated of Nav1.5 with ankyrin-G [61]. Moreover, Nav1.5 E1053K was not
properly targeted to the intercalated disc, implicating an ankyrin-G-
basedpathway forNav1.5 targeting in cardiomyocytes [61]. In summary,
ﬁndings from the brain, heart, and pancreas identify ankyrin polypep-
tides as critical nodes for regulation ofmembrane excitability for normal
physiology as well as demonstrate how defects in these pathways un-
derlie human pathophysiology. As ankyrins are expressed far beyond
these tissues, future studies will likely yield additional linkages between
these genes and other disease etiologies.
6. Caveolin-3 and type 9 long QT syndrome
Caveolae (“little caves”) are invaginations of the plasma mem-
brane critical to membrane endocytosis, cholesterol homeostasis,
cell signaling, and tumorigenesis [93,94]. The primary coat proteins
of caveolae are encoded by three genes: CAV1 (caveolin-1), CAV2
(caveolin-2) and CAV3 (caveolin-3) [95–98]. While caveolin-1 and
caveolin-2 are expressed in most cell types, caveolin-3 is primarily
expressed in muscle tissue [98]. Structurally, caveolin proteins are
similar, with an N-terminal domain, a scaffolding domain, and hydro-
phobic domain, and a C-terminal domain [99]. Caveolin-3 has been
linked with Duchenne muscular dystrophy, rippling muscle disease,
and idiopathic hyperCKemia [100–103]. At a molecular level, caveolin
co-puriﬁes with a number of cardiac membrane proteins, including
Nav1.5, HCN4 pacemaker channel, NCX, InsP3R, Kv1.5, PMCA, Cav1.2,
and TRP channels [104–111]. Caveolin-3 knockout mice display
abnormal cardiac T-tubule organization, [112,113]moderate cardiomy-
opathy, [93] and skeletal muscle myopathy [112,114]. Similar to these
ﬁndings in caveolin-deﬁcient mice, humans harboring CAV3 variants
display parallel phenotypes, [100–103] suggesting a role for caveolin
in human cardiac arrhythmias.
In 2006, Vatta and colleagues screened “genotypenegative” LQTSpro-
bands for potential variants in CAV3 [115]. These individuals displayed a
variety of cardiac phenotypes, including non-exertional syncope, sinus
bradycardia, and prolonged QTc intervals [115]. Four mutations wereidentiﬁed and termed LQT9 [115]. Prior to these ﬁndings, it had been
demonstrated that caveolin-3 associated with Nav channels, [111]
leading to further investigation of caveolin-3 and Nav1.5 interactions in
the cardiomyocyte. Studies by Vatta and others demonstrated that
caveolin-3 and Nav1.5 co-localize and co-immunoprecipitate in vivo
[111]. Furthermore, it was determined that the N-terminal domain of
caveolin-3 was required for interaction with Nav1.5 [115]. Heterologous
overexpression of both Nav1.5 and caveolin-3 in HEK cells produced a
two- to three-fold increase in late Na+ current, likely contributing to
the QT prolongation and cardiac arrhythmias observed in CAV3mutation
carriers [115]. It remains to be determined whether CAV3 mutations
result in abnormal subcellular targeting (since CAV3 mutations do not
disrupt association with Nav1.5 [115]), whether CAV3mutations alloste-
rically affect Nav channels, or whether cardiac dysfunction results from
altered localization of other caveolin-3-associated ion channels to the
sarcolemma. Of note, two recent studies have found an associated
between CAV3mutations and sudden infant death syndrome [116,117].
7. α-syntrophin and type 12 long QT syndrome
Syntrophins are a family of cytoplasmic adapter proteins that link
the actin-based cytoskeleton (via the dystrophin-associated com-
plex) to the extracellular matrix. Syntrophins have an internal PDZ
domain that has been demonstrated to interact with the C-terminal
region of Nav channels, including Nav1.4 and Nav1.5 [118,119]. Inter-
estingly,mdxmice (lacking dystrophin) display loss of cardiomyocyte
Nav1.5 expression from the peripheral sarcolemma, [119] presumed
to result from dysregulation of syntrophin. In addition to Nav1.5,
syntrophins have been linked to a number of ion channels; namely,
the plasma membrane calcium ATPase (PMCA) and neuronal nitric
oxide synthase (nNOS) [120–122]. Since nitric oxide (NO) directly af-
fects late INa in LQT3 (where pathogenic mutations in SCN5A accentu-
ate late INa), this connection is relevant to topic [123]. Additionally,
variants of CAPON (NOS1AP), a nNOS regulatory protein, have been
linked with QT interval regulation in genome-wide association stud-
ies [124,125]. Direct sequencing of α-1 syntrophin (SNTA1) in a num-
ber of “genotype negative” LQTS patients (see above) identiﬁed a
novel missense mutation, A390V, in a patient presenting with synco-
pe and QTc prolongation (now termed LQT12) [123]. This mutation
was found to decrease association of α-1 syntrophin with PMCA4b
and nNOS. Additionally, A390V increased Nav1.5 nitrosylation, as
well as increased persistent INa in cardiomyocytes [123]. It is believed
that this Nav1.5 dysregulation is the underlying cellular mechanism
for LQT12. Considering the number of ion channels known to associ-
ate with α-1 syntrophin, it is possible that other forms of cardiac dys-
function may be attributable to dysfunction in α-1 syntrophin.
8. Conclusion
Cardiovascular therapies including anti-platelet drugs, statins,
renin–angiotensin system antagonists, beta-blockers, and thrombolytic
agents developed in this past century have decreased cardiovascular-
based mortality over the past ﬁfty years. However, cardiovascular
disease remains the leading cause of death in the United States. Cardiac
ion channels and transporters regulate membrane excitability and
therefore would appear to represent a critical family of targets for
anti-arrhythmia therapy. Unfortunately, ion channel antagonists have
been unsuccessful in decreasing mortality in patients at risk for cardiac
sudden death — and in select cases have actually increased mortality
[126]. It is well established that macromolecular signaling complexes,
composed of adaptor proteins, ion channels, and signaling molecules,
are essential the creation, maintenance, and regulation of local micro-
environments in a number of cell types. The identiﬁcation of mutations
and variants within a larger ion channel complex has provided valuable
insights into the molecular basis of human disease. Based on the data
discussed in this review, we propose that non-conventional cellular
728 C.F. Kline, P.J. Mohler / Biochimica et Biophysica Acta 1838 (2014) 723–730pathways that indirectly regulate cardiac membrane ion channels and
transporter activities (ankyrins, spectrins, and syntrophins) may serve
as exciting new routes to tune cellular excitability in both congenital
and acquired forms of cardiovascular disease.
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